Pergolide
Ergot-derived Dopamine Receptor Agonist — NERVOUS SYSTEM
Also known as: LY 127809, LY-127,809, LY127,809, pergolide mesilate, pergolide mesylate, permax
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Pergolide is an ofm drug in the Ergot-derived Dopamine Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1988. Its mechanism of action is classified as Dopamine Agonists. DrugCentral lists 34 molecular targets, including DRD3, Htr7 and Drd3. Recorded indications include Parkinsonism.
- Approval status: ofm (first approved 1988 by the FDA).
- Drug class: Ergot-derived Dopamine Receptor Agonist.
- Mechanism of action: Dopamine Agonists.
- Molecular targets: DRD3, Htr7, Drd3 and Drd1|Drd3|Drd5|Drd4|Drd2 (34 listed in DrugCentral).
- Indications: Parkinsonism.
- ATC code: N04BC02 (Dopamine agonists).
- Molecular formula: C19H26N2S; molecular weight 314.50 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Parkinsonism
Contraindications (12)
- Breastfeeding (mother)
- Conduction disorder of the heart
- Fibrosis of pleura
- Heart valve disorder
- Kidney disease
- Orthostatic hypotension
- Pericardial effusion
- Pericarditis
- Pleural Effusions
- Pleurisy
- Renal fibrosis
- Retroperitoneal fibrosis
Mechanism & targets
| Mechanism of action (MoA) | Dopamine Agonists |
|---|---|
| Established pharmacologic class | Ergot-derived Dopamine Receptor Agonist |
Molecular targets (34)
| Target | Gene | Action | Activity |
|---|---|---|---|
| D(3) dopamine receptor | DRD3 | agonist | EC50 9.00 |
| 5-hydroxytryptamine receptor 7 | Htr7 | agonist | Ki 9.00 |
| D(3) dopamine receptor | Drd3 | unknown | IC50 8.62 |
| Dopamine receptor | Drd1|Drd3|Drd5|Drd4|Drd2 | unknown | IC50 8.51 |
| 5-hydroxytryptamine receptor 1A | HTR1A | unknown | Ki 8.50 |
| D(2) dopamine receptor | Drd2 | unknown | Kd 8.40 |
| D(2) dopamine receptor | DRD2 | agonist | EC50 8.30 |
| 5-hydroxytryptamine receptor 2B | HTR2B | unknown | EC50 8.20 |
| 5-hydroxytryptamine receptor 2A | HTR2A | unknown | EC50 8.10 |
| 5-hydroxytryptamine receptor 1D | HTR1D | unknown | Ki 7.90 |
| 5-hydroxytryptamine receptor 1A | Htr1a | unknown | IC50 7.82 |
| 5-hydroxytryptamine receptor 6 | HTR6 | unknown | Ki 7.75 |
| Dopamine receptor | DRD2|DRD1 | unknown | IC50 7.74 |
| Alpha-2B adrenergic receptor | ADRA2B | unknown | Ki 7.50 |
| 5-hydroxytryptamine receptor 6 | Htr6 | agonist | Ki 7.50 |
| 5-hydroxytryptamine receptor 1B | Htr1b | unknown | Ki 7.40 |
| Cerebral cortex alpha adrenergic receptor | ADRA1A|ADRA2A | unknown | IC50 7.39 |
| Adrenergic receptor alpha-2 | Adra2b|Adra2c|Adra2a | unknown | IC50 7.39 |
| D(2) dopamine receptor | DRD2 | unknown | IC50 7.32 |
| Alpha-2A adrenergic receptor | ADRA2A | unknown | Ki 7.30 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1988-12-30 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N04BC02 | NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Dopamine agonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Gambling disorder | 124.3 |
Chemical structure
| Molecular formula | C19H26N2S |
|---|---|
| Molecular weight | 314.50 g/mol |
| CAS number | — |
| InChIKey | YEHCICAEULNIGD-MZMPZRCHSA-N |
| PubChem CID | 47811 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Pergolide used for?
DrugCentral lists the following indications for Pergolide: Parkinsonism.
How does Pergolide work?
Pergolide is classified as Dopamine Agonists; its molecular targets in DrugCentral include DRD3 (agonist), Htr7 (agonist), Drd3 and Drd1|Drd3|Drd5|Drd4|Drd2.
When was Pergolide first approved?
Pergolide was first approved by the FDA in 1988.
What drug class does Pergolide belong to?
Pergolide is in the Ergot-derived Dopamine Receptor Agonist class.
What is the chemical formula of Pergolide?
Pergolide has the molecular formula C19H26N2S and a molecular weight of 314.50 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2105 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1275 — compound record and bioactivity
- PubChem CID 47811 — chemical identifiers
- DrugBank DB01186 — drug record
- FDA UNII 24MJ822NZ9 — substance identity
- DailyMed: FDA labels for Pergolide — current prescribing information (label search)
- UniProt P35462 (DRD3) — target protein
- UniProt P08908 (HTR1A) — target protein
- UniProt P14416 (DRD2) — target protein
- UniProt P41595 (HTR2B) — target protein
- UniProt P28223 (HTR2A) — target protein
- UniProt P28221 (HTR1D) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.